Upgrade to SI Premium - Free Trial

Barclays calls Sarepta Therapeutics (SRPT) data 'encouraging,' reiterates Equalweight rating

March 25, 2026 4:04 PM
Barclays analyst Eliana Merle reiterated an Equalweight rating and $20.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "Early ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles